15 results about "Hypervariable region" patented technology

This invention relates to the field of bioengineering technology, specifically to a recombinant adenovirus displaying a large antigen fragment on its capsid surface, its construction method, and its applications. The HVR1 and HVR5 regions of the hexon hypervariable region of this virus are replaced by gene fragments containing exogenous genes; each exogenous gene fragment has a flexible linker attached to both ends, and the gene sequence of the flexible linker is shown in SEQ ID No. 1. By precisely locating the naturally variable HVR1 and HVR5 loop regions exposed on the surface of the hexon protein as insertion sites, and supplementing them with flexible linkers, the core problem of exogenous sequence insertion disrupting the stability of the hexon structure is successfully solved. This allows for stable packaging to produce viral particles with high titers and infectivity, enabling the development of a new generation of highly efficient and safe capsid-displaying adenovirus vaccines.

The invention discloses a strain identification method based on a 16S rRNA (ribosomal Ribonucleic Acid) hypervariable region. According to the invention, a plurality of hypervariable regions of 16S rRNA are integrated, the distinguishing ability of specific strains in different variable regions and other strains belonging to the same genus is researched through a molecular evolutionary tree method, and finally, the combination of different hypervariable regions can be found, so that the purpose of identifying the specific strains at the species level is achieved.

The invention discloses a microbial community identification method and system, and particularly relates to the technical field of microbiomics. A hidden Markov model database constructed on the basis of multiple types of ribosome RNA sequences is adopted for global search, a huge whole genome database in the prior art is replaced, and the size of the database is reduced; moreover, the hypervariable region sequence is extracted from the identified ribosome RNA sequence in a targeted manner, and the extracted sequence data and the quality information in the original sequencing data are pasted back, so that the hypervariable region sequence file containing the complete quality information is generated. The sequence data contains sequence information for identification, and a ribosome RNA marker gene sequence can be accurately identified and extracted from metagenome or metatranscriptome sequencing data; the original sequencing data can be used for a traditional amplicon analysis process, and can also support downstream deep analysis, so that seamless connection with the traditional amplicon analysis process is realized.

The disclosure relates, inter alia, to recombinant adenoviruses having capsid proteins engineered to include an albumin-binding moiety such that the albumin-binding moiety is present on the outer surface of the recombinant adenovirus capsids. Also described are pharmaceutical compositions comprising the recombinant adenoviruses, and methods of using the recombinant adenoviruses to treat genetic diseases and disorders.

The invention provides a sheep-derived component rapid quantitative detection method based on dual real-time fluorescent PCR. According to the method, a single-copy nuclear gene GAPDH is taken as a target spot, a sheep specific primer and a probe are designed in a hypervariable region of the single-copy nuclear gene GAPDH, and an internal reference primer and a probe capable of identifying various common animal-derived components are designed in a conserved region of the single-copy nuclear gene GAPDH. As the target and the internal reference are located in the same gene and coexist in the same cell according to the proportion of 1: 1, quantitative deviation caused by gene copy number difference or expression fluctuation in a traditional two-step method is remarkably reduced. The detection strategy constructed by the invention has double advantages of specific recognition and broad-spectrum reference, is clear in quantitative basis and simple and convenient to operate, is suitable for rapid recognition and quantitative adulteration analysis of sheep-derived components in meat products, and has wide application prospects and supervision values.

The invention provides preparation and application of an adenovirus non-structural protein, and aims at a novel chimpanzee adenovirus to screen the non-structural protein capable of detecting the titer of the chimpanzee adenovirus with high sensitivity and strong specificity. Immunofluorescence detection is carried out on the virus titer through the antibody prepared from the non-structural protein, the result is close to the detection result of a fluorescence counting method of flow cytometry, compared with detection of hypervariable region protein antibodies and whole virus antibodies in existing structural protein, the accuracy and sensitivity of detection are remarkably improved, very high specificity can be kept, and the method is suitable for large-scale popularization and application. Therefore, the chimpanzee adenovirus titer can be detected more simply, conveniently and efficiently.

Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.

The present invention provides live attenuated vaccines for the prophylactic treatment of Chikungunya virus infections. The vaccines comprise a genetically modified Chikungunya virus that has a reduced replication capacity due to a mutation or deletion in the R5 region of the hypervariable domain of nsP3, a nonstructural protein that interacts with host factors. The inventors have indeed discovered that the R5 region of the hypervariable domain of nsP3, a nonstructural protein that interacts with host factors, is critical for CHIKV replication and pathogenesis. Specifically, the inventors have shown that the R5 region is required for the interaction of nsP3 with FHL1, BIN1 and CD2AP, three host proteins that are involved in the regulation of actin cytoskeleton and membrane trafficking. These host proteins are expressed in muscle and joint tissues, which are the main targets of CHIKV infection and inflammation. By mutating or deleting the R5 region of nsP3, the inventors have generated a genetically modified CHIKV (CHIKV-ΔR5) that has a reduced replication capacity and virulence compared to the WT virus. Moreover, the inventors have demonstrated that CHIKV-ΔR5 is able to elicit a strong neutralizing antibody response and protect mice from lethal challenge with WT virus. The present invention also provides screening methods for identifying test substances that are capable of inhibiting the interaction between nsP3 and FHL1, CD2AP and BIN1, wherein the selected test substances would be suitable for the treatment of CHIKV infections.

The invention discloses an Ad4-55 / Ad7-3 type tetravalent recombinant adenovirus vaccine and an application of the Ad4-55 / Ad7-3 type tetravalent recombinant adenovirus vaccine. The preparation method comprises the following steps: replacing a fifth hypervariable region of an HAdV-4 hexon in an HAdV-4 genome with a second hypervariable region of an HAdV-55 hexon to obtain a recombinant adenovirus Ad4-55; and replacing the first hypervariable region of the HAdV-7 hexon in the HAdV-7 genome with the first hypervariable region of the HAdV-3 hexon, so as to obtain the recombinant adenovirus Ad7-3. And mixing the recombinant adenovirus Ad4-55 and the recombinant adenovirus Ad7-3 to obtain the tetravalent recombinant adenovirus vaccine. Experiments prove that when the tetravalent recombinant adenovirus vaccine prepared by the invention is used for immunizing mice, high-level specific IgG antibodies and neutralizing antibodies can be induced. According to the present invention, the important application value is provided for the prevention and control of HAdV-3, HAdV-7, HAdV-4 and HAdV-55.

The invention relates to the technical field of bioengineering, in particular to the technical field of bioengineering, and particularly relates to a recombinant adenovirus with a capsid surface displaying an oversized fragment antigen, a construction method and application. An HVR1 region and an HVR5 region of a Hexon hypervariable region of the virus are respectively replaced by gene segments containing exogenous genes; in the gene segment, the two ends of the exogenous gene are respectively connected with a flexible connection segment, and the gene sequence of the flexible connection segment is as shown in SEQ ID No.1. HVR1 and HVR5 ring regions which are accurately positioned to be exposed on the surface of Hexon protein and have natural variability are used as insertion sites, and a flexible connecting fragment is supplemented, so that the core problem that the stability of a Hexon structure is damaged by insertion of an exogenous sequence is successfully solved, and virus particles with high titer and infection activity can be stably packaged and produced; a new generation of efficient and safe capsid display type adenovirus vaccine can be developed.

To provide engineered meganucleases.SOLUTION: Provided is an engineered meganuclease that recognizes and cleaves a recognition sequence within an intron of the human T cell receptor alpha gene located 5 ' upstream of TRAC exon 1, wherein said engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit binds to a first recognition half-site of said recognition sequence and comprises a first hypervariable region, and wherein said second subunit binds to a second recognition half-site of said recognition sequence and comprises a second hypervariable region.SELECTED DRAWING: None

This application describes a technology relating to treating neurofibromatosis type 1 and particularly, but not exclusively, to compositions and methods for gene replacement therapy treatments of patients having NF1-related tumors, for example, new recombinant adeno-associated virus vectors comprising a neurofibromatosis type 1 GAP-related domain fused to a Ras hypervariable region and use thereof to treat neurofibromatosis type 1.

This invention relates to the field of biological protein application technology, and discloses the application of flagellin hypervariable region H as an intramolecular adjuvant in vaccine preparation. The amino acid sequence of flagellin hypervariable region H is shown in SEQ ID NO.3, and the nucleotide sequence of the gene encoding flagellin hypervariable region H is shown in SEQ ID NO.4. This invention also discloses an expression cassette, recombinant vector, recombinant cells, or recombinant bacteria containing the gene encoding flagellin hypervariable region H. This invention uses the aforementioned flagellin hypervariable region H as an intramolecular adjuvant in vaccine preparation. This invention connects flagellin hypervariable region H to an antigenic epitope to obtain a fusion protein. Compared with existing technologies, the solubility and activity of the fusion protein are improved. Simultaneously, this invention overcomes the expression form of inclusion bodies in existing E. coli expression systems, eliminating the need for subsequent refolding and assembly, thus simplifying the vaccine preparation process.

The application discloses a kind of paragallinarievaccines and preparation method thereof, the paragallinarievaccines include A type paragallinarie, B type paragallinarie and C type paragallinarie HMTp210 hypervariable region protein and avian pathogenic escherichia coli ghost.The application uses three serotypes HMTp210 hypervariable region recombinant protein and avian pathogenic escherichia coli ghost (especially O78 type avian pathogenic escherichia coli ghost) in combination, synergistically enhances humoral and cellular immunity, provides more broad-spectrum protection, while reaching the protection effect equivalent to white oil adjuvant, significantly improves injection safety, avoids the granuloma and other side reactions of white oil adjuvant, realizes the technical goal of "equivalent protection, better safety".

This invention discloses a method and system for identifying microbial communities, particularly relating to the field of microbiome technology. By employing a Hidden Markov Model database constructed based on multiple types of ribosomal RNA sequences for global searching, it replaces the massive whole-genome databases of existing technologies, reducing database size. Furthermore, this invention generates a hypervariable region sequence file containing complete quality information by targeting and extracting hypervariable regions from the identified ribosomal RNA sequences and then back-linking the extracted sequence data with the quality information from the original sequencing data. The sequence data contains sequence information for identification, enabling accurate identification and extraction of ribosomal RNA marker gene sequences from metagenomic or metatranscriptomical sequencing data. The original sequencing data can be used for traditional amplicon analysis workflows and also supports downstream in-depth analysis, achieving seamless integration with traditional amplicon analysis workflows.